Premenstrual Syndrome Treatment Market by Drug Type, Type, Distribution Channel

Description

List of Tables

[192 Pages Report] The Premenstrual Syndrome Treatment Market size was estimated at USD 1.72 billion in 2023 and expected to reach USD 1.79 billion in 2024, at a CAGR 4.35% to reach USD 2.32 billion by 2030.

Premenstrual syndrome (PMS) comprises a range of physical, mental, and emotional changes or symptoms that occur in the few weeks before a woman's menstrual cycle. Symptoms may vary widely among women and can significantly impact daily functioning activities and quality of life. Treatment for PMS is thus multifaceted and personalized, aiming to alleviate specific symptoms and improve overall well-being. It ranges from lifestyle adjustments, dietary changes, and stress management to pharmacological interventions. Increased awareness and education about PMS and its impact on women's health and well-being and changing societal attitudes towards menstrual health and wellness have accentuated the need for comprehensive treatment options. Advances in medical research lead to more effective and personalized treatments, and government support for facilitating improvements in healthcare infrastructure and accessibility, including telehealth services, has encouraged more women to seek treatment. However, regulatory hurdles and safety concerns surrounding new and existing treatments may impede the widespread adoption of PMS treatment. Furthermore, variability in PMS symptoms and treatment efficacy makes standardized treatments challenging. However, key players are developing treatments that are tailored to individual genetic, hormonal, and lifestyle factors and researching effective natural, dietary, and lifestyle interventions that have fewer side effects. Creating digital platforms and apps for symptom tracking, therapy, and treatment plans can further boost the adoption of PMS treatment options among women,

KEY MARKET STATISTICS
Base Year [2023]	USD 1.72 billion
Estimated Year [2024]	USD 1.79 billion
Forecast Year [2030]	USD 2.32 billion
CAGR (%)	4.35%

Drug Type: Emerging utilization of oral contraceptives for managing PMS symptoms due to their dual role in birth control and symptom management

Analgesics, particularly nonsteroidal anti-inflammatory drugs (NSAIDs), are an essential component in the pharmacological treatment of PMS as they are commonly used to alleviate physical discomfort and pain associated with PMS. These medications are effective in reducing cramps, breast tenderness, and muscle pain by inhibiting the production of prostaglandins, substances known to cause inflammation and pain. Selective serotonin reuptake inhibitors (SSRIs) represent prominent antidepressants prescribed for PMS management, specifically targeting emotional and mood-related symptoms. SSRIs increase the levels of serotonin in the brain, a neurotransmitter that can affect mood and social behavior. They are particularly useful for women experiencing severe pre-menstrual dysphoric disorder (PMDD), a more extreme form of PMS, and have shown efficacy in reducing irritability, mood swings, depression, and anxiety. Oral contraceptives (birth control pills) and ovarian suppression agents are frequently utilized in PMS and PMDD treatment. These medications work by regulating or suppressing ovulation and, therefore, hormonal fluctuations that can trigger PMS symptoms. Oral contraceptives, combined with estrogen and progestin, help in achieving hormone balance, reducing the severity of physical and emotional symptoms. Meanwhile, gonadotropin-releasing hormone (GnRH) agonists are another class of ovarian suppression agents that significantly reduce ovarian hormone production and are often used in severe cases of PMDD.

Distribution Channel: Emerging preference for e-Commerce distribution channels due to customer need for convenient shopping

The e-Commerce platform has emerged as a significant distribution channel for premenstrual syndrome (PMS) treatment products. This channel facilitates easy access to a wide range of PMS treatment options available across the globe. Customers appreciate the convenience of browsing and purchasing products from the comfort of their own homes. Moreover, e-Commerce platforms often offer detailed product information, reviews, and comparisons, assisting consumers in making informed decisions. The ability to discreetly purchase and receive products enhances the appeal of this channel for individuals seeking PMS treatment options. Retail pharmacies remain a crucial distribution channel for PMS treatment products. This traditional channel allows consumers to obtain over-the-counter (OTC) and prescription medications with ease. Pharmacists play an integral role by providing professional advice, answering questions, and offering recommendations for managing PMS symptoms. The immediate availability of products and personal interaction with healthcare professionals make retail pharmacies a preferred choice for many individuals. In addition, retail pharmacies often stock a wide range of products and cater to various patient preferences and treatment requirements.

Regional Insights

In the Americas, the U.S. and Canada represent key nations for PMS treatment, characterized by high awareness and a strong focus on research and development in the pharmaceutical and medical sectors. The U.S. is notable for its diversity in treatment approaches, including over-the-counter (OTC) medications, prescription drugs, and natural supplements, representing the country's emphasis on personal choice and holistic health. Countries in the Americas witness ongoing investment in digital health solutions, such as mobile apps for PMS tracking and management. EU countries exhibit a strong preference for evidence-based medicine with a growing interest in natural and alternative treatments and a focus on advancing cutting-edge research in the realm of healthcare technology. There is a notable trend towards personalized medicine, leveraging genetic testing to tailor PMS treatment. Stringent regulations for the development and efficiency of medical devices, pharmaceutical preparations, and drugs in the EU have created a standardized architecture for innovations in the EU region. In the Middle East and Africa, cultural sensitivities and varying levels of healthcare accessibility impact the treatment landscape. The Asia Pacific region showcases a growing awareness and openness towards addressing PMS, with countries such as China, Japan, and India leading the market. Traditional remedies and herbal treatments still hold significant importance in China and India. However, there is an increasing shift towards clinically approved medications and holistic wellness approaches. Investment in women's health startups, particularly in India and China, has seen a rise, reflecting the growing market potential.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Premenstrual Syndrome Treatment Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Premenstrual Syndrome Treatment Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Premenstrual Syndrome Treatment Market, highlighting leading vendors and their innovative profiles. These include AA Pharma Inc., Alfa Pharma GmbH, Asarina Pharma AB., ASKA Pharmaceutical Co., Ltd., Aurobindo Pharma, Bayer AG, Cadila Pharmaceuticals., Comforte Cream by PMS4PMS, LLC, Dr. Reddy's Laboratories Inc., GlaxoSmithKline plc, Intas Pharmaceuticals Ltd., Lupin Limited, Mylan N.V., Par Pharmaceutical, Inc, Pfizer Inc., Samphire Neuroscience, Shine Pharmaceuticals Limited, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., The Himalaya Drug Company, and Vitane Pharmaceuticals, Inc..

Market Segmentation & Coverage

This research report categorizes the Premenstrual Syndrome Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

Drug Type
- Antidepressants
- Diuretics
- Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
- Oral Contraceptives & Ovarian Suppression Agents

Type
- Over-the-Counter
- Prescription

Distribution Channel
- E-commerce
- Hospitals
- Retail Pharmacies

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Premenstrual Syndrome Treatment Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Premenstrual Syndrome Treatment Market?

3. What are the technology trends and regulatory frameworks in the Premenstrual Syndrome Treatment Market?

4. What is the market share of the leading vendors in the Premenstrual Syndrome Treatment Market?

5. Which modes and strategic moves are suitable for entering the Premenstrual Syndrome Treatment Market?

Product Code: MRR-4F1ADAF481D9

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Increasing awareness of diagnosis regarding premenstrual syndrome
  - 5.1.1.2. Easy availability of PMS treatment products through online channels
- 5.1.2. Restraints
  - 5.1.2.1. Issues associated with product recalls for PMS drugs and devices
- 5.1.3. Opportunities
  - 5.1.3.1. Advancements in therapy for PMS and the emergence of novel drugs
  - 5.1.3.2. Adoption of wearable technology and the proliferation of digital health
- 5.1.4. Challenges
  - 5.1.4.1. Societal barriers and stigmatization regarding PMS management
5.2. Market Segmentation Analysis
- 5.2.1. Drug Type: Emerging utilization of oral contraceptives for managing PMS symptoms due to their dual role in birth control and symptom management
- 5.2.2. Distribution Channel: Emerging preference for e-Commerce distribution channels due to customer need for convenient shopping
5.3. Market Disruption Analysis
5.4. Porter's Five Forces Analysis
- 5.4.1. Threat of New Entrants
- 5.4.2. Threat of Substitutes
- 5.4.3. Bargaining Power of Customers
- 5.4.4. Bargaining Power of Suppliers
- 5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis

6. Premenstrual Syndrome Treatment Market, by Drug Type

6.1. Introduction
6.2. Antidepressants
6.3. Diuretics
6.4. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
6.5. Oral Contraceptives & Ovarian Suppression Agents

7. Premenstrual Syndrome Treatment Market, by Type

7.1. Introduction
7.2. Over-the-Counter
7.3. Prescription

8. Premenstrual Syndrome Treatment Market, by Distribution Channel

8.1. Introduction
8.2. E-commerce
8.3. Hospitals
8.4. Retail Pharmacies

9. Americas Premenstrual Syndrome Treatment Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Premenstrual Syndrome Treatment Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Premenstrual Syndrome Treatment Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
- 12.3.1. Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder
- 12.3.2. Thirty Madison Delivers Continuity Of Care For Thousands Through Strategic Asset Purchase From The Pill Club, Strengthening Its Position In Women's Health
- 12.3.3. London-Based Neurotech Start-Up Develops Medical Device For Menstrual Symptoms
12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

13.1. Key Company Profiles
13.2. Key Product Portfolio